| Literature DB >> 26539223 |
Byungjin Joh1, Eun Sang Jeon1, Su Hye Lim2, Yu Lee Park3, Wansu Park4, Han Chae5.
Abstract
Objectives. A review on studies related to the use of Mori folium, the leaves of Morus alba, was conducted with the goal of identifying new clinical applications in Korean medicine. Methods. Global literature search was conducted using three electronic databases up to January 2015 with the term Morus alba and its Korean terms. KM literatures including textbooks and standard pharmacopoeia were separately hand-searched and reviewed to provide comparison. Data were extracted according to predetermined criteria, and clinical uses were standardized with ICD-10 categories. Results. 159 potentially relevant studies were identified, and 18 articles including 12 ethnopharmacologic and 6 clinical studies were finally included in this analysis. Ethnopharmacologic studies from 8 countries provided 17 clinical uses. We found that five out of six clinical trials were related to diabetes and suggested a moderate short-term to mild long-term effect. And 43 Korean texts also provided 156 clinical uses in 35 categories including ocular and respiratory disorders. Discussion and Conclusions. Though majority of the clinical uses were also found in Korean medicine literature, treatment of infertility, jaundice, cognitive disorder, and hyperpigmentation was found to be effective and diabetes with Morus alba was recognized to have clinical importance.Entities:
Year: 2015 PMID: 26539223 PMCID: PMC4619920 DOI: 10.1155/2015/379268
Source DB: PubMed Journal: Evid Based Complement Alternat Med ISSN: 1741-427X Impact factor: 2.629
Predefined criteria for data extraction.
| Ethnopharmacologic studies | ||||
|---|---|---|---|---|
| Study & text details | Uses† | Culture or nationality | ||
| ID (e.g., first author) | Disorder treatment | Nationality of subjects | ||
|
| ||||
| Clinical studies | ||||
| Study details | Uses | Population | Material | Outcome measures & results |
|
| ||||
| ID (e.g., first author) | Disorder treatment | Diagnosis | Material used (intervention & control) | Primary outcome measures |
†Only single use of Mori folium herb was retrieved.
Figure 1Data extraction process of the current review.
Ethnopharmacologic studies on Mori folium.
| Author (year) | Relevant ICD-10 category | Description of use in original article | Culture/nationality |
|---|---|---|---|
|
Menale and Muoio (2014) [ | I10 essential (primary) hypertension | High blood pressure | Italy |
|
| |||
| Bibi et al. (2014) [ | R05 cough | The leaves were boiled in water (Joshanda) and given for cough due to throat pain | Pakistan |
|
| |||
| Ullah et al. (2013) [ | J40 bronchitis, not specified as acute or chronic | White mulberry leaves are expectorant, encouraging the loosing and coughing up of catarrh, and are prescribed in China as a treatment for coughs. The leaves are also taken to treat fever, sore and inflamed eyes, sore throats, headache, dizziness, and vertigo | Pakistan |
|
| |||
| Tetik et al. (2013) [ | n/a | Reducing† | Turkey |
|
| |||
| Gakuya et al. (2013) [ | H54 visual impairment including blindness | Blindness | Kenya |
|
| |||
| Oliveira et al. (2012) [ | C80 malignant neoplasm, without specification of site | Cancer | Brazil |
|
| |||
| Sathiyaraj et al. (2012) [ | N46 male infertility†† | Anti-infertility | India |
|
| |||
| Sharma et al. (2012) [ | R17 unspecified jaundice | Leaf juice mixed with one cup of curd is given once a day till the patient is cured | India |
|
| |||
| Adhikari et al. (2008) [ | L81 other disorders of pigmentation | Hyperpigmentation | Nepal |
|
| |||
| Au et al. (2008) [ | M79 other soft tissue disorders | Neuritis | China |
|
| |||
|
Arýkan et al. (2009) [ | E10 type 1 diabetes mellitus | Type 1 diabetes in children | Turkey |
|
| |||
| Samy et al. (2008) [ | T63 toxic effect of contact with venomous animals | Snakebite treatment | India |
†It might refer to weight reduction, fetal reduction, and use in conjunction with orthopedic reduction, fever reduction, or cicatrizer.
††Gender is not explicitly mentioned, but study describes male infertility.
Clinical trials using Mori folium or derived products.
| Author & year | Study type | Condition & ICD-10 | Participants & sample size | Material used | Dosage & duration | JADAD score | Primary outcome measures | Main results |
|---|---|---|---|---|---|---|---|---|
| Banu et al. (2015) [ | CC | Type 2 diabetes (E11) | 48 type 2 diabetics on oral medication (28 intervention + 20 black tea placebo) | Tea | 1 cup (70 mL), single dose | — | Plasma glucose change before meal with tea and 90 minutes afterwards | Plasma glucose levels in control and intervention groups before meal and 90 minutes after being changed from 178.55 ± 35.61 to 287.20 ± 56.37 (control) and 153.50 ± 48.10 to 210.21 ± 58.73 (intervention) ( |
|
| ||||||||
| Chung et al. (2013) [ | RCT | Glucose suppression (n/a) | 50 healthy people between ages 20 and 50 (10 + 10 + 10 + 10 + 10)† | Aqueous extract | 0 g, 1.25 g, 2.5 g, and 5 g extract, single dose | 3 (1 + 0 + 1 + 0 + 1) | Plasma glucose level at 0, 15, 30, 60, 90, and 120 minutes after maltose intake | Intake of 2.5 g or 5 g with maltose suppressed glucose elevation significantly compared to control ( |
|
| ||||||||
| Asai et al. (2011) [ | RCT + CR†† | Diabetes NOS (E14) | 76 adults with 110–140 mg/dL FPG (38 intervention + 38 placebo) | Enriched extract | 6 mg DNJ equivalent extract, t.i.d., 12 weeks | 4 (1 + 0 + 1 + 1 + 1) | Fasting plasma glucose, insulin, HbA1c, glycated albumin, 1,5-anhydroglucitol at weeks 0, 4, 8, 12, and 16 | No significant difference was found between groups except for 1, 5 AG at weeks 8 & 12 ( |
|
| ||||||||
| Srichaikul (2012) [ | RCT | Other mental disorders (F06) | 20 women with mild cognitive impairment (5 + 5 + 5 + 5)††† | Extract | 200 mg, q.d., 3 months | 2 (1 + 0 + 1 + 0 + 0) | SAGE, MMSE scale score changes at start and end of treatment period | Mean SAGE score rank changed from 14.1, 12.7, 7.3, and 7.9 to 17.70, 8.7, 11.0, and 4.6. Mean MMSE score rank changed from 17.4, 10.5, 6.7, and 7.4 to 17.6, 10.1, 8.5, and 5.8. |
|
| ||||||||
| Nakamura et al. (2009) [ | CR | Glucose suppression (n/a) | 10 healthy volunteers | Ethanol extract | 1.2 or 3 g, single dose | — | Plasma glucose (Glu.) & insulin (Ins.) (every 30 minutes for 3 hours) | Glucose and insulin elevation was suppressed in 1.2 and 3 g group compared to control at different time points (1.2 g Glu.: 30, 120 min/Ins.: 30 min/3 g Glu.: 30.90, 120 min/Ins.: 30 min/all |
|
| ||||||||
|
Yang and Han (2006) [ | RCT | Type 2 diabetes (E11) | 25 type 2 diabetics on oral medication (14 intervention + 9 control) | Aqueous extract | 500 mg b.i.d., 12 weeks | 4 (1 + 0 + 1 + 1 + 1) | Fasting plasma glucose, HbA1c, serum lipids at start and end of treatment period | HbA1c, LDL-C, and TG decreased in intervention compared to control ( |
RCT, randomized controlled trial; CR, crossover; CC, case-controlled. All medications were taken orally.
†Group 1: 0 g extract with 75 g maltose. Group 2: 1.25 g extract with 75 g maltose. Group 3: 2.5 g extract with 75 g maltose. Group 4: 5 g extract with 75 g maltose. Group 5: 5 g extract 30 minutes before 75 g maltose. Group 5 cannot be considered as part of double-blind design.
††Dual phase design; only the RCT part is analyzed in this table.
†††Group 1: silkworm weavers given Mori folium extracts (SWE). Group 2: silkworm weavers given placebo (SWP). Group 3: nonsilkworm weavers given Mori folium extracts (NSWE). Group 4: nonsilkworm weavers given placebo (NSWP).
Korean medical literature on Mori folium.
| Author | Published | Name of the book | Relevant ICD-10 category |
|---|---|---|---|
| Unknown | 0th–2nd |
| R50 fever of other and unknown origin |
|
| |||
| Ge Hong | 3rd |
| A09 other gastroenteritis and colitis of infectious and unspecified origin |
|
| |||
| Tao Hongjing | 2nd-3rd |
| T63 toxic effect of contact with venomous animals |
|
| |||
| Su Jing | 7th |
| R52 pain, not elsewhere classified |
|
| |||
| Meng Shen | 7-8th |
| R63 symptoms and signs concerning food and fluid intake |
|
| |||
| Chen Zangqi | 8th |
| K52 other noninfective gastroenteritis and colitis |
|
| |||
| Cao Beng | 8th |
| K52 other noninfective gastroenteritis and colitis |
|
| |||
| Rihuazi | 10th |
| M25 other joint disorders, not elsewhere classified |
|
| |||
| Unknown | 10–13th |
| M06 other rheumatoid arthritis |
|
| |||
| Unknown | 14th |
| R61 hyperhidrosis |
|
| |||
| Yu Hyo-Tong | 15th |
| N61 inflammatory disorders of breast |
|
| |||
| Liu Wentai | 16th |
| A09 other gastroenteritis and colitis of infectious and unspecified origin |
|
| |||
| Chén Jiä-Mó | 16th |
| H04 disorders of lacrimal system |
|
| |||
| Li Chan | 16th |
| H04 disorders of lacrimal system |
|
| |||
| Li Shizhen | 16th |
| R05 cough |
|
| |||
| Miu Xi-Yong | 17th |
| R61 hyperhidrosis |
|
| |||
| Miu Xi-Yong | 17th |
| H11 other disorders of conjunctiva |
|
| |||
| Wu, Youxing | 17th |
| R50 fever of other and unknown origin |
|
| |||
| Heo Jun | 17th |
| K52 other noninfective gastroenteritis and colitis |
|
| |||
| Lun Zhu | 18th |
| H04 disorders of lacrimal system |
|
| |||
| Wú Yíluò | 18th |
| T14 injury of unspecified body region |
|
| |||
| Huang Gongxiu | 18th |
| H54 visual impairment including blindness (binocular or monocular) |
|
| |||
| Guö Rû-Cóng | 19th |
| R61 hyperhidrosis |
|
| |||
| Unknown | 19th |
| R50 fever of other and unknown origin |
|
| |||
| Yang Shitai | 19th |
| H11 other disorders of conjunctiva |
|
| |||
| Chen Qirui | 19th |
| H54 visual impairment including blindness (binocular or monocular) |
|
| |||
| Beijing Institute of Chinese Medicine | 20th |
| H54 visual impairment including blindness (binocular or monocular) |
|
| |||
| Szechuan Chinese Materia Medica Editing Committee | 20th |
| H54 visual impairment including blindness (binocular or monocular) |
|
| |||
| Shin Gil-Gu | 20th |
| R50 fever of other and unknown origin |
|
| |||
| Lee Sang-In | 20th |
| H54 visual impairment including blindness (binocular or monocular) |
|
| |||
| Nan Jing Traditional Chinese Medical School | 20th |
| J00 acute nasopharyngitis [common cold] |
|
| |||
| Lee Sang-In | 20th |
| J00 acute nasopharyngitis [common cold] |
|
| |||
| Zhen Xunying | 20th |
| J00 acute nasopharyngitis [common cold] |
|
| |||
| Nationwide Chinese Medical Herb Compilation Committee | 20th |
| J00 acute nasopharyngitis [common cold] |
|
| |||
| Jiangxi Health and Welfare Ministry | 20th |
| J00 acute nasopharyngitis [common cold] |
|
| |||
| Zhou jinzhong | 20th |
| J00 acute nasopharyngitis [common cold] |
|
| |||
| Lin Tongguo | 20th |
| J00 acute nasopharyngitis [common cold] |
|
| |||
| Color Illustrated Chinese Medicine Pharmacopoeia Editing Committee | 20th |
| J00 acute nasopharyngitis [common cold] |
|
| |||
| Editing Committee | 20th |
| J00 acute nasopharyngitis [common cold] |
|
| |||
| Great Collection of Chinese Medicine Editing Committee | 20th |
| J00 acute nasopharyngitis [common cold] |
|
| |||
| National Korean Medical College Textbook Editing Committee | 20th |
| J00 acute nasopharyngitis [common cold] |
|
| |||
| Kim Ho-Chul | 21th |
| R50 fever of other and unknown origin |
|
| |||
| Song and Kim | 21th |
| J02 acute pharyngitis |
English translations of author and text names were used whenever available.